NOVEL TARGETS FOR LARGE SCALE F18 PRODUCTION

Information

  • Research Project
  • 6016527
  • ApplicationId
    6016527
  • Core Project Number
    R43CA080431
  • Full Project Number
    1R43CA080431-01A1
  • Serial Number
    80431
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/12/1999 - 25 years ago
  • Project End Date
    6/30/2000 - 24 years ago
  • Program Officer Name
    TORRES-ANJEL, MANUEL J.
  • Budget Start Date
    7/12/1999 - 25 years ago
  • Budget End Date
    6/30/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/12/1999 - 25 years ago
Organizations

NOVEL TARGETS FOR LARGE SCALE F18 PRODUCTION

Several significant changes in the last year indicate that the production and distribution of fluorodeoxyglucose (FDG) for Positron Emission Tomography (PET) will be a significant growth business over the next ten years. Among these changes are the increased use of FDG in nuclear medicine and the improving reimbursement environment for PET, including the reimbursement for lung cancer. In order to meet the need for increased 18F fluoride ion production, accelerators will have to be developed or modified that are capable of producing this isotype at the lowest cost per millicurie with high reliability. We propose an intensive development of gridded accelerator window supports to enable the development in Phase II of high power (approximately 800 W) 11 MeV proton only targets for the production of 18F fluoride ion. The product of the proposed research plus increases in available beam current from internal developments at CTI will result in an accelerator capable of producing FDG at a substantially lower cost per millicurie than is currently available. The focus of this application is targets for 11 MeV protons due to the currently mature, low-cost, commercially viable and highly reliable accelerator technology at CTI. PROPOSED COMMERCIAL APPLICATIONS: The proposed research will result in a marketable and manufacturable upgrade to our current, commercially viable product. The reduction in cost of FDG that this development provides will stimulate the accelerator market, as well as the market for scanners that rely on this radiopharmaceutical.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    CTI, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    KNOXVILLE
  • Organization State
    TN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    37922
  • Organization District
    UNITED STATES